Neuland Laboratories Limited
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
What Neuland files
- Others73
- Investor Meet46
- Important30
- Updates16
- Board Meeting8
- PPTs8
Neuland Laboratories Limited has announced participation in upcoming group analyst and institutional investor meetings, including the Emkay Global Investors Meeting and the ICICI Securities Hyderabad Healthcare Day, both scheduled to be held in Hyderabad.
Neuland Laboratories has committed ₹126 Cr via internal accruals to acquire ~134 acres in Kakinada for future growth. Management also holds a right of first refusal for an additional 66 acres, pushing potential total land to ~200 acres. This bold land bank expansion signals strong long-term capacity scaling ahead.
Crisil Ratings has reaffirmed Neuland Labs' long-term credit rating at CRISIL A+, with its outlook revised to 'Positive'. This upgrade in outlook suggests an improving credit profile for the company. The short-term rating of CRISIL A1 has also been reaffirmed. This is a positive signal for investors regarding the company's...
Neuland Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
US FDA inspected Neuland Laboratories' Unit 3 facility. One observation was noted for procedural improvements in water and environmental monitoring for new organisms. The company will address this finding.